Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
For full access to this article login to GEN Select now.
Personalized Arthritis Therapy
With Blockbuster Drugs in Jeopardy Firms Look to Pharmacogenetics
- Recent reports of an increased risk of heart attack with the Cox-2 inhibiting drugs Vioxx and Celebrex have resulted in a huge setback for arthritis therapeutics. These drugs had become staples for the treatment of osteoarthritis (OA) and rheumatoid arthritis, both debilitating inflammatory diseases. It seems that the ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.